NEWS
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
15 out of the 16 patients had a reduction of their tumors (target lesions)
79% of EVX-01's vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches
A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response (p=0.00013)
EVX-01 as a novel potential melanoma treatment holds a significant commercial potential for Evaxion
Data will be discussed at a webinar with key opinion leader Professor Georgina V. Long on September 18, 2024
11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate
15 out of the 16 patients had a reduction of their tumors (target lesions)
79% of EVX-01's vaccine targets triggered a targeted immune response, which compares very favorably to what is seen with other approaches
A positive correlation was observed between the AI-Immunology™ platform predictions and neoantigen immune response (p=0.00013)
EVX-01 as a novel potential melanoma treatment holds a significant commercial potential for Evaxion
Data will be discussed at a webinar with key opinion leader Professor Georgina V. Long on September 18, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2012Followers
101Following
17KVisitors
Follow